Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

Article  Google Scholar 

Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404.

Article  Google Scholar 

Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–13.

Article  Google Scholar 

Agostini A, Godard C, Laurendeau C, Benmahmoud Zoubir A, Lafuma A, Levy-Bachelot L, et al. Two-year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database. Eur J Contracept Reprod Health Care. 2018;23(6):421–6.

Article  Google Scholar 

Hofmann B, Apter D, Bitzer J, Reinecke I, Serrani M, Höchel J, et al. Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route. Eur J Contracept Reprod Health Care. 2020;25(6):417–26.

Article  Google Scholar 

Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011;17(1):121–37.

Article  Google Scholar 

Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012. Obstet Gynecol. 2015;126(5):917–27.

Article  Google Scholar 

Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30(11):2527–38.

Article  Google Scholar 

Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care. 2014;19(1):5–14.

Article  Google Scholar 

Critchley HO, Wang H, Kelly RW, Gebbie AE, Glasier AF. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 1998;13(5):1210–7.

Article  Google Scholar 

Sheppard BL. Endometrial morphological changes in IUD users: a review. Contraception. 1987;36:1–10.

Article  Google Scholar 

Apter D, Briggs P, Tuppurainen M, Grunert J, Lukkari-Lax E, Rybowski S, Gemzell-Danielsson K. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril. 2016;106(1):151-7.e5.

Article  Google Scholar 

Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97(3):616-22.e1-3.

Article  Google Scholar 

Gemzell-Danielsson K, Buhling KJ, Dermout SM, Lukkari-Lax E, Montegriffo E, Apter D. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents. Contraception. 2016;93(6):507–12.

Article  Google Scholar 

Bradley JE, Alam ME, Shabnam F, Beattie TSH. Blood, men and tears: keeping IUDs in place in Bangladesh. Cult Health Sex. 2009;11:543–58.

Article  Google Scholar 

Higgins JA, Sanders JN, Palta M, Turok DK. Women’s sexual function, satisfaction, and perceptions after starting long-acting reversible contraceptives. Obstet Gynecol. 2016;128:1143–51.

Article  Google Scholar 

Polis CB, Hussain R, Berry A. There might be blood: a scoping review on women’s responses to contraceptive-induced menstrual bleeding changes. Reprod Health. 2018;15:114.

Article  Google Scholar 

Schmidt EO, James A, Curran KM, Peipert JF, Madden T. Adolescent experiences with intrauterine devices: a qualitative study. J Adolesc Health. 2015;57:381–6.

Article  Google Scholar 

Carvalho NM, Chou V, Modesto W, Margatho D, Garcia EAL, Bahamondes L. Relationship between user satisfaction with the levonorgestrel-releasing intrauterine system and bleeding patterns. J Obstet Gynaecol Res. 2017;43(11):1732–7.

Article  Google Scholar 

Sanders JN, Adkins DE, Kaur S, Storck K, Gawron LM, Turok DK. Bleeding, cramping, and satisfaction among new copper IUD users: a prospective study. PLoS ONE. 2018;13(11):e0199724.

Article  Google Scholar 

Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122:1214–21.

Article  Google Scholar 

Davie JE, Walling MR, Mansour DJ, Bromham D, Kishen M, Fowler P. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther. 1996;18:150–9.

Article  Google Scholar 

Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;7:CD001751.

Google Scholar 

Grimes DA, Hubacher D, Lopez LM, Schulz KF. Non-steroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database Syst Rev. 2006;4:CD006034.

Google Scholar 

Godfrey EM, Folger SG, Jeng G, Jamieson DJ, Curtis KM. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception. 2013;87(5):549–66.

Article  Google Scholar 

Hu X, Li L, Zou Y, Wu S. A multicenter comparative study of UCu200, TCu380A, and medicated γ-IUD devices inserted immediately after vacuum aspiration. Int J Gynaecol Obstet. 2013;122(1):65–9.

Article  Google Scholar 

Wang LY, Li SZ, Wu SY, Zhao YH, Wang Y. A random control study of indomethacin-containing MYCu intrauterine contraceptive device for 60 months [in Chinese]. Zhonghua Yi Xue Za Zhi. 2013;93(7):496–9.

Google Scholar 

Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413–21.

Article  Google Scholar 

Dannhardt G, Kiefer W. Cyclooxygenase inhibitors – current status and future prospects. Eur J Med Chem. 2001;36:109–26.

Article  Google Scholar 

Jaydess Summary of Product Characteristics. Bayer. July 2020. https://www.medicines.org.uk/emc/product/5297/smpc. Accessed Oct 2021.

European Medicines Agency. Guideline on Bioanalytical Method Validation. European Medicines Agency; 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed 27 Sep 2021.

US FDA. FDA CDER – Bioanalytical Method Validation – Guidance for Industry. US FDA; 2018. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 27 Sep 2021.

European Medicines Agency, GCP Inspectors Working Group. Reflection Paper for Laboratories that Perform the Analysis or Evaluation of Clinical Trial Samples. February 28, 2012. European Medicines Agency; 2012. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-laboratories-perform-analysis-evaluation-clinical-trial-samples_en.pdf. Accessed 27 Sep 2021.

Organisation for Economic Co-operation and Development. OECD Principles on Good Laboratory Practice (ENV/MC/CHEM(98)17). Organisation for Economic Co-operation and Development; 1997. https://one.oecd.org/document/ENV/MC/CHEM(98)17/en/pdf. Accessed 27 Sept 2021.

International Council for Harmonisation. ICH Harmonised Tripartite Guideline, Guideline for Good Clinical Practice E6 (R2). ICH. 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 27 Sep 2021.

García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628–36.

Article  Google Scholar 

Indomethacin Summary of Product Characteristics. Ratiopharm. May 2013. https://s3.eu-central-1.amazonaws.com/prod-cerebro-ifap/media_all/48289.pdf. Accessed Jul 2021.

INDOCIN prescribing information. March 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016059s100lbl.pdf. Accessed Oct 2021.

Bastianelli C, Farris M, Rosato E, Varliero F, Del Savio MC, Facchinetti F, Grandi G. The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study. Eur J Contracept Reprod Health Care. 2022;27:16–22.

Article  Google Scholar 

Grandi G, De Fata R, Varliero F, Del Savio MC, Facchinetti F. Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an Italian service for family planning. Gynecol Endocrinol. 2020;36(12):1086–9.

Article  Google Scholar 

Duckitt K, Collins S. Menorrhagia. BMJ Clin Evid. 2012;2012:0805.

Google Scholar 

Bateson D, Harvey C, Trinh L, Stewart M, Black KI. User characteristics, experiences and continuation rates of copper intrauterine device use in a cohort of Australian women. Aust N Z J Obstet Gynaecol. 2016;56(6):655–61.

Article  Google Scholar 

Jaydess Prescribing Information. Bayer. July 2021. https://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf. Accessed Oct 2021.